# Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

> **NCT00865280** · PHASE3 · TERMINATED · sponsor: **Paratek Pharmaceuticals Inc** · enrollment: 143 (actual)

## Conditions studied

- Skin Diseases, Infectious

## Interventions

- **DRUG:** PTK 0796
- **DRUG:** linezolid
- **DRUG:** moxifloxacin

## Key facts

- **NCT ID:** NCT00865280
- **Lead sponsor:** Paratek Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04-04
- **Primary completion:** 2010-04-15
- **Final completion:** 2010-04-15
- **Target enrollment:** 143 (ACTUAL)
- **Why stopped:** Terminated
- **Last updated:** 2021-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00865280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00865280, "Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00865280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*